Cytokinetics CEO Robert I. Blum disposes of USD 490,950 in common shares

By Public Technologies
  • Cytokinetics President and CEO Robert I. Blum exercised stock options for 7,500 shares at USD 10.6 on Sept. 28, 2026.
  • Blum sold 7,500 shares at USD 65.46 the same day.
  • Directly held common shares totaled 278,544 following the transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-26-000097), on September 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk